Dissemin is shutting down on January 1st, 2025

Published in

Wiley, Biomedical Chromatography, 8(37), 2023

DOI: 10.1002/bmc.5642

Links

Tools

Export citation

Search in Google Scholar

Development of simultaneous quantitative analytical method for metabolites of hexosamine biosynthesis pathway in lung cancer cells using ultra‐high‐performance liquid chromatography‐tandem mass spectrometry

Journal article published in 2023 by Yerim Seo, Eun Kyoung Chung ORCID, Byung Hwa Jung ORCID
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Orange circle
Postprint: archiving restricted
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

AbstractThe hexosamine biosynthesis pathway (HBP) is a glucose metabolism pathway that produces uridine diphosphate N‐acetyl glucosamine (UDP‐GlcNAc). Substantial changes in HBP, including elevated HBP flux and UDP‐GlcNAc levels, are associated with cancer pathogenesis. Particularly, cancer cells expressing oncogenic Kirsten rat sarcoma virus (KRAS) are highly dependent on HBP for growth and survival. To differentiate between HBP metabolites in KRAS wild‐type (WT) and mutant (MT) lung cancer cells, a simultaneous quantitative method for analyzing seven HPB metabolites was developed using ultra‐high‐performance liquid chromatography‐tandem mass spectrometry. A simple method without complicated preparation steps, such as derivatization or isotope labeling, was optimized for the simultaneous analysis of highly hydrophilic HBP metabolites, and the developed method was successfully verified. The intra‐ and inter‐day coefficients of variation were less than 15% for all HBP metabolites, and the recovery was 89.67–114.5%. All results of the validation list were in accordance with ICM M10 guidelines. Through this method, HBP metabolites in lung cancer cells were accurately quantified, and it was confirmed that all HBP metabolites were upregulated in KRAS MT cells compared with KRAS WT lung cancer cells. We expect that this will be a useful tool for metabolic research on cancer and for the development of new drugs for cancer treatment.